MML Investors Services LLC Lowers Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

MML Investors Services LLC cut its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 51.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,124 shares of the company’s stock after selling 6,596 shares during the quarter. MML Investors Services LLC’s holdings in Twist Bioscience were worth $277,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in TWST. Signaturefd LLC boosted its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Twist Bioscience during the second quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Twist Bioscience by 1,173.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock valued at $154,000 after purchasing an additional 3,134 shares during the period. Finally, Blue Trust Inc. increased its position in shares of Twist Bioscience by 224.3% during the 3rd quarter. Blue Trust Inc. now owns 3,810 shares of the company’s stock valued at $188,000 after purchasing an additional 2,635 shares during the last quarter.

Insider Activity

In related news, CFO Adam Laponis sold 856 shares of the company’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. This represents a 1.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. The trade was a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 99,659 shares of company stock worth $4,484,602 over the last ninety days. Company insiders own 3.92% of the company’s stock.

Analyst Ratings Changes

TWST has been the topic of a number of research analyst reports. Scotiabank boosted their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. Evercore ISI increased their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $48.90 on Thursday. The business’s fifty day moving average is $45.51 and its 200 day moving average is $46.72. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of -13.58 and a beta of 1.82. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.